Retinal pigment epithelial cell replacement therapy (Cell Cure Neurosciences)

N/A

Report date: 2023/01/12 16:08:16

Base Information

Drug NameRetinal pigment epithelial cell replacement therapy (Cell Cure Neurosciences)
Drug Alias NameOpRegenRG-6501
ClassificationCell and gene therapy > Cell therapy > Source of cells > Embryonic stem cell-derivedCell and gene therapy > Cell therapy > Somatic cell > Retinal pigment epithelial cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsGeographic AtrophyMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCell Cure NeurosciencesLineage Cell Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdGenentech Inc
Inactive CompaniesN/A
Active IndicationsGeographic AtrophyMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A